Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: an open-label phase IIa trial (Lupsenic)

Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: an open-label phase IIa trial (Lupsenic)

Abstract Background Lupus animal model has shown that arsenic trioxide (ATO), a treatment of acute promyelocytic leukaemia, could be effective in SLE. This is the first clinical study to determine the safety and efficacy of a short course of intravenous ATO in patients with active SLE. Methods This...

Full description

Bibliographic Details
Main Authors: Mohamed Hamidou, Antoine Néel, Joel Poupon, Zahir Amoura, Mikael Ebbo, Jean Sibilia, Jean-Francois Viallard, Benjamin Gaborit, Christelle Volteau, Jean Benoit Hardouin, Eric Hachulla, François Rieger
Format: Article
Language:English
Published: BMC 2021-03-01
Series:Arthritis Research & Therapy
Subjects:
Systemic lupus erythematosus
Autoimmune diseases
Treatment
Arsenic trioxide
Phase II clinical trial
Online Access:https://doi.org/10.1186/s13075-021-02454-6

Internet

https://doi.org/10.1186/s13075-021-02454-6

Similar Items